Hydroxyurea mobile directly observed therapy versus standard monitoring in patients with sickle cell anemia: a phase 2 randomized trial.

Philip SasiAbel MakubiRaphael Zozimus SangedaMariam Y NgaejeBruno P MmbandoJoseph SokaCaterina RosanoAlex S MagesaSharon E CoxJulie MakaniEnrico M Novelli

Published in: Communications medicine (2024)

m-DOT did not increase adherence to HU treatment. We recommend that further testing in larger trials with a longer follow up period be undertaken.

Keyphrases

chronic kidney disease
sickle cell disease
metabolic syndrome
combination therapy
glycemic control
replacement therapy
weight loss
smoking cessation